(Q48482385)

11 February 2018

title

Increased cortical inhibition induced by apomorphine in patients with Parkinson's disease (English)

1 reference

11 February 2018

1 reference

1 reference

Manfredi L

1

1 reference

11 February 2018

Garavaglia P

series ordinal

2

1 reference

11 February 2018

Beretta S

series ordinal

3

1 reference

11 February 2018

Pellegrini G

series ordinal

4

1 reference

11 February 2018

publication date

1 February 1998

1 reference

11 February 2018

Neurophysiologie Clinique

published in

1 reference

11 February 2018

volume

28

1 reference

11 February 2018

issue

1

1 reference

11 February 2018

page(s)

31-38

1 reference

11 February 2018

Parkinson's disease rigidity: magnetic motor evoked potentials in a small hand muscle

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0987-7053%2897%2989576-7

7 January 2021

Magnetic brain stimulation: the silent period after the motor evoked potential.

1 reference

https://api.crossref.org/works/10.1016%2FS0987-7053%2897%2989576-7

7 January 2021

Somatosensory evoked potentials at rest and during movement in Parkinson's disease: evidence for a specific apomorphine effect on the frontal N30 wave

1 reference

https://api.crossref.org/works/10.1016%2FS0987-7053%2897%2989576-7

7 January 2021

The apomorphine test in parkinsonian syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0987-7053%2897%2989576-7

7 January 2021

Primate models of movement disorders of basal ganglia origin

1 reference

https://api.crossref.org/works/10.1016%2FS0987-7053%2897%2989576-7

7 January 2021

The corticomotoneurone connection is normal in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0987-7053%2897%2989576-7

7 January 2021

The silent period in spastic, rigid, and normal subjects during isotonic and isometric muscle contractions

1 reference

https://api.crossref.org/works/10.1016%2FS0987-7053%2897%2989576-7

7 January 2021

Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0987-7053%2897%2989576-7

7 January 2021

Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0987-7053%2897%2989576-7

7 January 2021

Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0987-7053%2897%2989576-7

7 January 2021

Latency and duration of the muscle silent period following transcranial magnetic stimulation in multiple sclerosis, cerebral ischemia, and other upper motoneuron lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0987-7053%2897%2989576-7

7 January 2021

Muscle silent period in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0987-7053%2897%2989576-7

7 January 2021

Parkinsonism: onset, progression, and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0987-7053%2897%2989576-7

7 January 2021

The silent period in a muscle of the human hand

1 reference

https://api.crossref.org/works/10.1016%2FS0987-7053%2897%2989576-7

7 January 2021

Computer-aided determination of the silent period.

1 reference

https://api.crossref.org/works/10.1016%2FS0987-7053%2897%2989576-7

7 January 2021

Motor cortical inhibition and the dopaminergic system. Pharmacological changes in the silent period after transcranial brain stimulation in normal subjects, patients with Parkinson's disease and drug-induced parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0987-7053%2897%2989576-7

7 January 2021

The cortical silent period and amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0987-7053%2897%2989576-7

7 January 2021

Supplementary and primary sensory motor area activity in Parkinson's disease. Regional cerebral blood flow changes during finger movements and effects of apomorphine

1 reference

https://api.crossref.org/works/10.1016%2FS0987-7053%2897%2989576-7

7 January 2021

Parkinson's disease and somatosensory evoked potentials: apomorphine-induced transient potentiation of frontal components

1 reference

https://api.crossref.org/works/10.1016%2FS0987-7053%2897%2989576-7

7 January 2021

Characteristics of the silent period after transcranial magnetic stimulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0987-7053%2897%2989576-7

7 January 2021

Motor inhibition and excitation are independent effects of magnetic cortical stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0987-7053%2897%2989576-7

7 January 2021

Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0987-7053%2897%2989576-7

7 January 2021

10.1016/S0987-7053(97)89576-7

Identifiers

DOI

1 reference

11 February 2018

1 reference

11 February 2018